Login to Your Account



Depression Programs Bring in Good Money for Naurex, Prexa

By Catherine Shaffer


Thursday, May 12, 2011
CNS company Naurex Inc., of Evanston Ill., completed an $18 million Series A financing for Phase II trials of its lead depression compound, GLYX-13. At the same time, Prexa Pharmaceuticals, of Boston, landed a $7 million Series B to advance triple reuptake inhibitor PRX-12251 into Phase Ib.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription